Eli Lilly has increased the price of the weight-loss drug Mounjaro in the UK, with the highest monthly dose rising from £122 to £330, reflecting a 170% increase. Generally, retailers may negotiate discounts on the list price, possibly limiting the impact on consumers. The price change does not affect NHS payments, as a heavily-discounted rate has been negotiated for prescriptions. Mounjaro, which helps users feel full and lose approximately 20% of body weight, currently aids around 1.5 million people in the UK, primarily with private payment.
Eli Lilly announced a price increase for the weight-loss drug Mounjaro in the UK, raising the monthly cost from £122 to £330, a rise of up to 170%.
The price increase primarily affects private payers, as the NHS pays a negotiated discounted rate, allowing patients with prescriptions to avoid the list price hike.
Mounjaro helps individuals feel full, assisting in the loss of approximately 20% of their body weight, currently helping about 1.5 million users in the UK.
Eli Lilly justified the price increase by stating that the previous cost charged in the UK was significantly lower than that in other European countries.
Collection
[
|
...
]